Bicycle Therapeutics plc, a pharmaceutical company specializing in bicyclic peptide technology, will present two abstracts at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago from May 30 to June 3. The presentations include preliminary results from the Phase 1/2 Duravelo-1 study on Nectin-4-targeting zelenectide pevedotin (BT8009) plus pembrolizumab in certain urothelial cancer patients, and a Phase 2/3 study of the Bicycle® Drug Conjugate zelenectide pevedotin (BT8009) for patients with locally advanced or metastatic urothelial cancer.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicycle Therapeutics plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20250522152802) on May 22, 2025, and is solely responsible for the information contained therein.